Table 1. Baseline characteristics for all treated patients with advanced melanoma.
| Characteristics | Patients (n=37) |
|---|---|
| Gender (n (%)) | |
| Male | 23 (62) |
| Female | 14 (38) |
| Median age (years (range)) | 53 (18–85) |
| ECOG PS (n (%)) | |
| 0 | 15 (41) |
| 1 | 21 (57) |
| 2 | 0 (0) |
| 3 | 1 (3) |
| AJCC stage at study entry (n (%)) | |
| III | 4 (11) |
| IV | 21 (57) |
| Most common sites of disease (all lesions)a (n (%)) | |
| Lung | 24 (65) |
| Lymph node | 20 (54) |
| Liver | 12 (32) |
| Adrenal | 8 (22) |
| Median duration of diseaseb (years (range)) | 2.7 (0.2–12.9) |
| Prior therapy (n (%)) | |
| Systemic anticancer therapy | 26 (70) |
| Surgery | 36 (97) |
| Radiotherapy | 10 (27) |
| Number of prior systemic regimens | |
| None | 11 (30) |
| 1 | 13 (35) |
| 2 | 8 (22) |
| ⩾3 | 5 (13) |
AJCC=American Joint Committee on Cancer; ECOG PS=Eastern Cooperative Oncology Group performance status.
a
All target and nontarget lesions occurring with a frequency ⩾20%.
b
Years from initial diagnosis to first study treatment.